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Background. Rotavirus (RV) is the leading cause of diarrhea-related death in children worldwide and 95% of RV-associated
deaths occur in Africa and Asia where RV vaccines (RVVs) have lower efﬁcacy. We hypothesize that differences in intestinal micro-
biome composition correlate with the decreased RVV efﬁcacy observed in poor settings.
Methods. We conducted a nested, case-control study comparing prevaccination, fecal microbiome compositions between 6-
week old, matched RVV responders and nonresponders in rural Ghana. These infants’ microbiomes were then compared with
154 age-matched, healthy Dutch infants’ microbiomes, assumed to be RVV responders. Fecal microbiome analysis was performed
in all groups using the Human Intestinal Tract Chip.
Results. We analyzed ﬁndings in 78 Ghanaian infants, including 39 RVV responder and nonresponder pairs. The overall micro-
biome composition was signiﬁcantly different between RVV responders and nonresponders (FDR, 0.12), and Ghanaian responders
were more similar to Dutch infants than nonresponders (P = .002). RVV response correlated with an increased abundance of Strep-
tococcus bovis and a decreased abundance of the Bacteroidetes phylum in comparisons between both Ghanaian RVV responders and
nonresponders (FDR, 0.008 vs 0.003) and Dutch infants and Ghanaian nonresponders (FDR, 0.002 vs 0.009).
Conclusions. The intestinal microbiome composition correlates signiﬁcantly with RVV immunogenicity and may contribute to
the diminished RVV immunogenicity observed in developing countries.
Keywords. rotavirus vaccine; intestinal microbiome; mucosal immunity.
Rotavirus (RV) is the leading cause of diarrhea-related death in
children worldwide, with 95% of RV deaths occurring in low-
income countries in Africa and Asia [1]. Oral RV vaccines
(RVVs) have the potential to dramatically reduce the morbidity
and mortality caused by RV infection, but RVVs demonstrate
signiﬁcantly lower efﬁcacy in low-income countries [2]. Large
clinical efﬁcacy studies showed a combined vaccine efﬁcacy
against severe RV gastroenteritis ranging from 48% to 64%
for both Rotarix and RotaTeq vaccines in Africa and Asia
[3–5]. Emerging effectiveness data in Africa provides similar es-
timates of RVV protection [6]. This compares to an observed
efﬁcacy of 85%–98% against severe RV in trials in wealthier
countries in Latin America and Europe [7–10].
Understanding the pathophysiologic mechanism driving this
diminished efﬁcacy in developing countries is critical, because
even small improvements in vaccine efﬁcacy could increase
the number of children’s lives saved by the vaccine by hundreds
of thousands over the next 15 years [11]. There are several hy-
potheses as to why oral RVVs are underperforming in Africa
and Asia [12]. These include interference with the ﬁrst dose
of coadministered oral poliovirus vaccine, RVV immune re-
sponse suppression through high prevaccination levels of
serum immunoblogulin (Ig) G, including transplacentally de-
rived IgG, high levels of breast milk–derived RV-speciﬁc IgA,
and HLA blood group antigen type [13–16]. However, none
of these explanations have adequately and sufﬁciently explained
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the underperformance of RVV in developing countries, where
vaccine efﬁcacy can dip even lower than 50% in some settings.
One underexplored hypothesis is that the intestinal microbiome
may be modulating an infant’s immune response to the enteric
RVV [17]. We hypothesized that the composition of the intes-
tinal microbiome is correlated with RVV response, that RVV
responders have different intestinal microbes as compared
with nonresponders and that these dissimilarities may contrib-
ute to the decreased efﬁcacy of RVV found in resource-poor set-
tings. To test these hypotheses, we conducted a nested, case-
control study in Navrongo, Ghana, comparing the differences
in intestinal microbiome composition and diversity between
RVV seroconverters and nonseroconverters after vaccination
with the Rotarix vaccine. We then compared these infants’ mi-
crobiomes with those from a large group of age-matched
healthy infant from the Netherlands, where RVV response is
postulated to be high, similar to responses observed in other
Northern European countries [10, 18].
METHODS
Study Design and Participants
Ghanaian Infants
The original trial within which this trial was nested was con-
ducted in Navrongo, a rural setting in Northern Ghana where
>70% of the population belong to the lowest wealth quintile in
Ghana, in 2012. The neonatal and mortality rates are 24 and 46
deaths per 1000 live births, respectively [19].
All participating infants were healthy infants with a birth weight
> 2000 g and/or a gestational age >38 weeks. The infants were en-
rolled at 6 weeks of age in a previously reported phase IV random-
ized clinical trial conducted in 2012 in Navrongo to evaluate the
immunogenicity of the Rotarix vaccine after different dosing
schedules (at age 6 and 10 weeks, 10 and 14 weeks, or 6, 10,
and 14 weeks) (NCT01575197, clinicaltrials.gov) [20]. In this
trial, all infants received concomitant standard Expanded Program
on Immunization vaccinations, including the trivalent oral polio-
virus vaccine and pentavalent vaccine (diphtheria, tetanus, whole-
cell pertussis, hepatitis B, and Haemophilus inﬂuenza type).
Only infants from the 6- and 10-week and the 6-, 10-, and 14-
week dose arms of the clinical trial were included in this micro-
biome study. A serum samples was collected before the receipt
of the ﬁrst dose of vaccine (at 6 weeks of age) and serum was
collected again approximately 4 weeks after the last dose of vac-
cine (at age 14 or 18 weeks, depending on the study arm) for
anti-RV IgA antibody measurements. Fecal samples were col-
lected immediately before vaccination, at 6 weeks of age.
Infants were included in the study if during the original
study their guardians had consented to additional testing of
specimens in RV-vaccine related studies. Inclusion criteria fur-
ther mandated that a baseline fecal sample was available and
that there was no evidence of natural RV infection before vac-
cination (prevaccination IgA level ≥20 IU/mL). An IgA level
≥20 IU/mL was considered an indication of seroconversion
and a surrogate marker for RVV protection against severe RV
gastroenteritis [21].
Participating infants were then grouped as either RVV re-
sponders (postvaccination anti-RV IgA antibody ≥20 IU/mL)
or RVV nonresponders (postvaccination anti-RV IgA antibody
<20 IU/mL) and matched by hand in a 1:1 ratio using the follow-
ing ranked variables: number and timing of doses of vaccine re-
ceived (at age 6 and 10 weeks or 6, 10, and 14 weeks), sex, age at
vaccination, RV season (deﬁned as the date of the serum IgA level
obtained 28 days after the last vaccination, between 1 December
2012 and 1 March 2013), ethnicity, height and weight at enroll-
ment (including underweight, stunting, and wasting Z scores),
and whether the infant regurgitated the vaccine after administra-
tion. The exact mode of delivery data and breastfeeding practices
data are not known for the original Ghanaian study population.
However, all infants in Ghanawere delivered in the study hospital
where >95% of deliveries are vaginal, and almost all infants de-
livered vaginally are breastfed. The nested trials were approved by
the institutional review board of the Noguchi Memorial Institute
for Medical Research and the research was conducted in accor-
dance with good clinical practice guidelines.
Dutch Infants
In parallel, we compared the microbiome of both the Ghanaian
responder and nonresponder infants with those in a cohort of
healthy, age-matched Dutch control infants. The Dutch infants
had not received RVV, but were assumed to be RVV responders,
in line with ample clinical trial data demonstrating a >90% RVV
seroconversion rate in Northern European countries [7, 10].Fecal
samples for these control infants were collected at approximately
30 days of age as part of a previously published study (the Bibo
study) in which mothers and their children were followed up be-
ginning with the third trimester of pregnancy [22, 23]. Pregnant
women were recruited through midwife practices in Nijmegen
and surrounding areas in the Netherlands. All parents provided
written informed consent for participation in the study. The
study was approved by the ethical committee of the faculty of so-
cial sciences at the Radboud University in Nijmegen. The infants’
microbiomes were analyzed in the study using an identical pro-
tocol based on the Human Intestinal Tract Chip (HITChip) phy-
logenetic microarray [22]. Consent had been given for further use
of the samples, which were entirely anonymous in our analysis.
Laboratory Evaluations
Assays
Anti-RV IgA antibody was measured in serum using an en-
zyme-linked immunosorbent assay described elsewhere, with
values expressed in international units per milliliter [24, 25].
Fecal Microbiome and Enteric Pathogen Analysis
In Ghana, fecal samples were collected by community health
workers in infants’ homes, transported in a cool box, and frozen
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to −20°C within 24–48 hours of collection. All samples were
stored in 3% glycerol in frost-free freezers. Routine temperature
monitoring did not indicate any freeze-thaw cycles. In the
Netherlands, fecal samples were collected by parents at home
and immediately stored at −20°C. The samples were transport-
ed in coolers with freezing cartridges or dry ice for further stor-
age at −80°C. These procedures are both considered adequate
for fecal microbiome analysis [26].
The fecal samples were analyzed by means of HITChip mi-
croarrays in duplicate, as described elsewhere [27]. In brief, total
DNA was extracted from the fecal material by a repeated bead
beating procedure using a modiﬁed protocol for the QiaAmp
DNA MiniStool Kit (Qiagen), also as described elsewhere
[28]. The 16S ribosomal RNA gene was ampliﬁed using primers
that enabled incorporation of T7 promoter sequence at the 5-
terminus of the amplicon. RNA was transcribed with amino-
allyl modiﬁed nucleotides that were later coupled to cyanine
(Cy) 3 or Cy5 dyes. Labeled RNA was fragmented, and 2 sam-
ples, each carrying a different dye, were hybridized in duplicate
to the HITChip microarrays.
The HITChip microarray is a comprehensive and highly re-
producible phylogenetic microarray that enables the parallel
proﬁling and the semiquantitative analysis of >1100 phylotypes
representing all major intestinal phyla grouped in 130 genuslike
groups described for the human intestinal microbiome [27].
This high-throughput technique has been benchmarked with
ultradeep pyrosequencing of 16S ribosomal RNA amplicons
and next-generation parallel sequencing of intestinal metage-
nomes [29, 30]. After microarray hybridization, a sample was
accepted only if 2 independent hybridizations (labeled with
Cy5 and Cy3) correlated signiﬁcantly (>95% Pearson correla-
tion). This highly reproducible microbiome analysis allowed
for direct comparison of all samples described in this study.
Statistical Analysis
A χ2 test was used to determine statistically signiﬁcant differences
in baseline characteristics between Ghanaian RVV responders
and nonresponders. The Shannon diversity index was used to
measure the diversity of the microbiome per sample, including
richness and evenness, using the hybridization signal of all probes
included in the HITChip microarray [31]. Paired 2-tailed Student
t tests were used to evaluate statistical signiﬁcance.
Comprehensive multivariate statistical analyses were per-
formed using Canoco 5.0 software for Windows [32]. Genus-
level principal coordinate analysis and redundancy analyses
were performed to evaluate differences in the overall microbial
composition between the Ghanaian study groups (Ghanaian
RVV responders and nonresponders). The 130 genuslike bacte-
rial groups targeted by the HITChip microarray were used as
biological variables, and the matching variables named above
were used as background variables and visualized by means of
inverse distance-weighted interpolation of the variable values
over the component space. Monte Carlo permutation testing
was used to assess the signiﬁcance of the effect of these variables
in the data set.
Generalized linear models were used to identify individual
bacterial phyla and genuslike groups (class for Firmicutes) asso-
ciated with RV seroconversion, as differing signiﬁcantly either
between Ghanaian nonresponders and responders or between
the Ghanaian nonresponders and Dutch infants. P values cor-
rected for the false discovery rate (FDR) were used to correct for
multiple testing [33]. Bacterial taxa, whose log-transformed rel-
ative abundance was differed signiﬁcantly (FDR-corrected
P < .10) between the Ghanaian nonresponders and responders
or between the Ghanaian nonresponders and Dutch infants,
were considered correlated with RVV immunogenicity. These
statistical analyses were performed with the program R [34].
To evaluate the similarity between Ghanaian infants (nonre-
sponders and responders) and Dutch infants, we generated
Pearson correlation scores and then performed an analysis of
variance between Ghanaian nonresponders and responders.
RESULTS
Ghanaian Infants
A total of 234 infants (of which 74 were RVV responders) with
prevaccination fecal samples were available from the original
Ghana clinical trials and eligible for this study. A total of 52
RV responders were successfully matched to 52 nonresponders
in a 1:1 ratio based on the predeﬁned matching criteria. Of
those, a total of 78 samples (equaling 39 per-protocol matched
pairs) had sufﬁcient DNA of good enough quality to be success-
fully analyzed using the HITChip pipeline.
No signiﬁcant differences between the vaccine responders
and nonresponders in Ghana were identiﬁed for any of the mea-
sured variables and baseline characteristics as described in
Table 1. The diversity index (Shannon index) of the intestinal
microbiome did not differ between infants who were RVV re-
sponders and those who were nonresponders (mean [SD],
4.40 [0.24] vs 4.41 [0.25], respectively; P = .87).
In Ghana, a high abundance of the Bacteroidetes phylum
(FDR, 0.003), particularly several bacteria related to Bacteroides
and Prevotella species, were signiﬁcantly correlated with a lack
of RVV response (Figures 1 and 2). Conversely, the Bacilli phy-
lum (FDR, 0.027) correlated signiﬁcantly with RVV response,
speciﬁcally bacteria related to Streptococcus bovis (FDR = 0.008)
(Figures 1 and 2).
We further evaluated the high abundance of bacteria in the
Bacteroidetes phylum in nonresponder infants. Recent litera-
ture has suggested that many bacteria in the Bacteroidetes phy-
lum have a less immunogenic lipopolysaccharide (LPS) than
Enterobacteriacae, such as Escherichia coli [35]. We therefore
calculated an enterobacteria-Bacteroidetes ratio to provide a
rough estimate of the presence of toxigenic LPS in the micro-
biome and compared the ratios between all groups. The
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enterobacteria-Bacteroidetes ratio was signiﬁcantly higher in
the Ghanaian responder infants (P = .04) than in nonresponder
infants (Figure 1C).
Spearman correlation analyses were performed to assess
whether the actual titer of the IgA—as opposed to RV serocon-
version as a binary variable (≥20 IU/mL)—was correlated with
speciﬁc bacterial groups. The Spearman correlation results
showed that 33 genuslike bacterial groups were signiﬁcantly
correlated with RVV response (deﬁned as an FDR <0.200). As
with the results obtained when using IgA as a binary variable,
bacteria related to Streptococcus bovis (FDR, 0.070) were the
only bacteria whose abundance were correlated signiﬁcantly
(FDR, <0.1) with increased RVV titers. All other bacterial
groups were signiﬁcantly associated with lower RVV titers,
and ﬁndings in only 1 bacterial group (bacteria related to Xan-
thomonadaceae) differed from those of the statistical analysis
using IgA as a binary variable. Therefore, the Spearman corre-
lation analysis using absolute IgA titers both mirrored and con-
ﬁrmed the ﬁndings attained when evaluating IgA as a binary
variable with 20 IU/mL as a cutoff point. (Supplementary
Figure 1).
Finally, the genuslike principal coordinate analysis indicated
that the main variable differentiating the microbiome composi-
tion between the Ghanaian responders and nonresponders was
RVV seroconversion, as calculated with Monte Carlo permuta-
tion testing (P = .01; FDR 0.12). (Supplementary Figure 2).
None of the other environmental variables that were tested cor-
related with signiﬁcant microbiome differences.
Ghanaian Infants Compared With Dutch Infants
The Ghanaian infant microbiome compositions were then com-
pared with the fecal microbiomes of 154 healthy Dutch infants.
Of these Dutch infants, 62% were still receiving breast milk at 4
weeks of age, 42% were female, and 93% had been delivered
vaginally; their mean (SD) birth weight was 3619 (457)
g. When the Dutch infants were compared with the Ghanaian
infants, their overall microbiome composition was signiﬁcantly
more similar to that in the Ghanaian RVV responders than to
that in nonresponders (P = .002; Figure 1B).
We then evaluated which phyla and bacterial genus groups
differed signiﬁcantly between Dutch infants and Ghanaian
RVV nonresponders (see Supplementary Table 1) and subse-
quently assessed which of these bacterial groups also differed
signiﬁcantly in the comparison between Ghanaian RVV re-
sponders and nonresponders (Figure 3). At the phylum level,
bacilli were signiﬁcantly more abundant in both Ghanaian
RVV responders and Dutch infants than in nonresponder in-
fants (FDR for Dutch vs Ghanaian RVV nonresponders,
0.0002 ). The Bacteroidetes phylum was also signiﬁcantly
more abundant in Ghanaian nonresponders than both the Gha-
naian responders and the Dutch infants (FDR, 0.006).
At the genus level, all bacterial groups that differed signiﬁ-
cantly between Ghanaian nonresponders and responders
(FDR, <0.1) also differed signiﬁcantly between Ghanaian non-
responders and Dutch infants. Bacteria related to Streptococcus
bovis were more abundant in both Dutch infants and Ghanaian
responders than in the Ghanaian infants without an RVV im-
mune response (FDR, 0.0018). In parallel, several bacteria from
the Bacteroidetes phylum (FDR, 0.002), particularly the Bacter-
oides and Prevotella genera, were more abundant in the Ghana-
ian nonresponders than in the Dutch infants (all Figure 3).
Finally, the enterobacteria-Bacteroidetes ratio was also signiﬁ-
cantly higher (P < .01) in Dutch infants than in Ghanaian in-
fants without an RVV immune response (Figure 1C).
DISCUSSION
This study of Ghanaian infants demonstrates that the prevacci-
nation intestinal microbiome differs signiﬁcantly—on a genus-
like, phylum, and overall composition level—between RVV
responders and nonresponders in a rural, low-income setting
in sub-Saharan Africa and that these microbiome differences
are robustly recapitulated when Dutch infants are compared
with RVV nonresponders.
RVV response was positively associated with the Bacilli phy-
lum, speciﬁcally bacteria related to Streptococcus bovis. Several
bacterial groups were signiﬁcantly associated with a lack of
Table 1. Baseline Characteristics and Matching Characteristics of the 78
Infants Enrolled in the Nested Study in Ghana and Differences Between
RVV Nonresponders and Responders as Determined With χ2 Tests
Infants, No. (%)a
Characteristic
RVV
Nonresponders
RVV
Responders
P
Value
Total 39/78 (50) 39/78 (50) . . .
Sex >.99
Male 14/39 (36) 14/39 (36)
Female 25/39 (64) 25/39 (64)
Ethnicity >.99
Nankam 15/39 (38) 15/39 (38)
Kassem 24/39 (62) 24/39 (62)
Age at vaccination mean
(SD), d
42 (0.47) 43 (1.44) >.99
Vaccination schedule >.99
Arm 2: age 6 and 10 wk 12/39 (31) 12/39 (31)
Arm 3: age 6, 10, and 14
wk
27/39 (69) 27/39 (69)
RV season .36
Yes 31/39 (79) 34/39 (87)
No 8/39 (21) 5/39 (13)
Malnutrition .95
Underweight 1/39 (3) 0/39 (0) .31
Stunting 2/39 (5) 3/39 (8) .64
Wasting 1/39 (3) 1/39 (3) >.99
Wasting 1/39 (3) 1/39 (3) >.99
Abbreviations: RV, rotavirus; RVV, RV vaccine.
a Data represent No. (%) of infants unless otherwise specified.
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RVV response—namely, bacteria belonging to the Bacteroidetes
phlyum, especially several bacteria related to species from the
Bacteroides and Prevotella genera.
The high abundance of Bacteroidetes in the microbiome of
infants not responding to RVV is intriguing. Certain species
from that phylum have been shown to express a form of LPS
that is functionally and structurally different from the LPS ex-
pressed in some proteobacteria, such as E. coli [35, 36]. LPS is
present in the outer membrane of most gram-negative bacteria
and is a strong immunogenic stimulator of the innate immune
system [37]. LPS structure varies from species to species, and
variation—particularly in the lipid A core of LPS—can inﬂu-
ence LPS’ immunostimulatory capacity [38]. LPS derived from
several Bacteroidetes species has recently been shown to have an
impaired or even immune-inhibitory capacity to stimulate in-
ﬂammatory cytokines in vitro when compared with LPS derived
from E. coli [35].
Although our study could not measure infants’ microbiome
expression of a less toxigenic LPS, we chose to roughly evaluate
this phenomenon by comparing the ratio of all enterobacteria to
Bacteroidetes in each infant group. We did not compare speciﬁc
enterobacteria or Bacteroidetes species because of some cross-
hybridization at the species level in the HITChip microarray.
This enterobacteria-Bacteroidetes ratio was signiﬁcantly
increased in both the Ghanaian RVV responders and Dutch in-
fants compared with the nonresponders, raising the possibility
that early microbiome colonization with bacteria expressing a
less toxigenic or perhaps inhibitory form of LPS might be
down-regulating innate immune responses to the live attenuat-
ed RV contained in the vaccine. Alternatively, more toxic LPS
might be having an adjuvant effect on RVV responses in those
Ghanaian infants capable of eliciting an immunogenic response
to RVV.
Interestingly, in the Ghanaian responders, bacteria related
to Streptococcus bovis was signiﬁcantly correlated with RV
response. The Streptococcus bovis group belongs to the
S. bovis–Streptococcus equinus complex, which, like bacteria
with toxigenic LPS, such as the E. coli, Serratia, and Klebsi-
ella groups, can cross from being commensals to being op-
portunistic pathogens and whose cell surface proteins can
trigger inﬂammatory responses [39]. Although speculative,
these S. bovis–S. equinus complex bacteria could also be
priming the immune system or acting as natural vaccine
adjuvants.
Figure 1. Overall microbiome composition. A, Bar plot of the percentage of each phylum in the total microbiome composition for the Ghanaian rotavirus vaccine (RVV)
nonresponders (NR) and responders (R) and Dutch infants (NL). B, Ghanaian RVV responders are significantly more similar to Dutch infants than nonresponders. Y-axis
shows mean similarity score as calculated by means of Pearson correlation. C, Ghanaian RVV responders and Dutch infants have a significantly higher enterobacteria-
Bacteroidetes ratio than Ghanaian nonresponders. Y-axis shows the log-transformed ratio of all species of enterobacteria to all species of Bacteroidetes.
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An alternative hypothesis, given that the vaccines contain live
attenuated virus, is that these bacteria might be expressing blood
group antigens or glycans needed for RV replication, as has
recently been demonstrated with norovirus and RV [40, 41]. Un-
fortunately, FUT2 secretor status, which is epidemiologically asso-
ciated with RV gastroenteritis, is unknown among these infants.
Figure 2. A, Comparison of the relative abundance (median signal intensity) of all bacterial genuslike groups with a statistically significant (false discovery rate [FDR] <0.1)
difference in abundance between Ghanaian rotavirus vaccine (RVV) responders (R) and nonresponders (NR). Plots show means with standard errors. B, The FDR for each of the
significantly different genera.
Figure 3. A, Comparison of the relative abundance (median signal intensity) of all bacterial genuslike groups with a statistically significant (false discovery rate [FDR], < 0.1)
difference in abundance between both (1) Ghanaian rotavirus vaccine (RVV) responders (R) and nonresponders (NR) and (2) Dutch infants (NL) and Ghanaian RVV nonresponders
(NR). Plots show means with standard errors. B, FDRs for the significantly different genera.
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This study has some limitations, restricting the strength of
our ﬁndings. One of the most important is that, for the cohort
of Dutch infants, we do not have RVV immunogenicity data
and are predicting RVV response from randomized control
studies showing >90% RVV efﬁcacy in Europe [7, 10]. Because
these were all healthy, at-term infants, we do predict that they
would mount immune responses to RVV but are unable to
demonstrate this. In addition, the study lacks speciﬁc data on
breastfeeding and delivery practices for the infants in Ghana,
and these may be confounders in our study results. Neverthe-
less, because >95% of deliveries are vaginal and all infants deliv-
ered vaginally are breastfed in this cohort, we do not expect
mode of delivery and breastfeeding practices to be signiﬁcant
confounders in this study population. We also were not able
to match our infants in Ghana for maternal antibodies to RV,
such as breast milk anti-RV IgA and transplacentally acquired
anti-G1 RV IgG antibody. High levels of maternally derived an-
tibodies have been shown to diminish RVV immunogenicity,
which could be contributing to the lack of response observed
in our cohort and confounding the results [14, 15].
As another limitation, we used anti-RV IgA response as a
correlate of vaccine protection, which can be an imperfect sur-
rogate for vaccine efﬁcacy [21]. Clinical vaccine efﬁcacy would
require larger sample sizes and follow-up. In addition, the intes-
tinal microbiome is a complex ecosystem, and bacterial popula-
tions are in constant interplay with other intestinal inhabitants
and pathogens, such as archae and eukaryotic microbes. This
analysis of the microbiome did not evaluate the intestinal vi-
rome, fungiome, or parasites, and these could be immunologic
mediators and inﬂuence bacterial populations. Finally, the asso-
ciations between microbiome and RVV response are correlative
and not causative and taken at a single time-point—directly be-
fore vaccination in a very young infants with high variability in
their microbiome population. Nevertheless, our study used an
identical, standardized, and reproducible technique to measure
the intestinal microbiome in 2 geographic locations, and match-
ing for numerous demographic variables in Ghana helps mini-
mize possible study cofounders. As a consequence, our work is a
springboard to understanding the mechanistic relationships be-
tween the intestinal microbiome and oral RVV responses in vul-
nerable infant populations and a call for more research to
inform the design of evidence-based interventions to improve
RVV efﬁcacy worldwide.
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